SUMMARY
Malignant hyperthermia (MH) is an inherited pharmacogenetic disorder characterized by muscle rigidity and accelerated metabolism, together with associated secondary manifestations in susceptible individuals exposed to triggering agents such as inhalation anaesthetics and depolarizing muscle relaxants [1] . Denborough and co-workers [2] described a pedigree in which clinical MH segregated in an autosomal dominant manner. Development of in vitro contracture testing to determine susceptibility to MH [3, 4] has permitted the screening of relatives of probands presenting with clinical MH. Susceptibility is determined currently by the contracture response of living muscle tissue to in vitro exposure to halothane and, separately, to caffeine. From 1984, the standard method for these tests is described in the procedure recommended by the European Malignant Hyperthermia Group [5] . This designates patients to be MHS (susceptible), MHE (equivocal) and MHN (normal) according to whether they respond abnormally to both drugs, one drug alone, or neither drug, respectively. Before 1984, patients were characterized as either positive or negative for malignant hyperthermia susceptibility. These family studies have confirmed the autosomal dominant mode of inheritance of MH susceptibility [6, 7] . Recent developments in molecular genetics should enable the mapping of gene(s) responsible for the disorder. This might in turn result in noninvasive methods for the presymptomatic diagnosis of MH susceptibility.
In certain breeds of pig, a similar (but perhaps not identical) disorder has been described [8] . The porcine gene conferring halothane-induced MH susceptibility, HAL, is genetically linked to those encoding glucose phosphate isomerase, GPI, and the ryanodine receptor, RYR1 [9, 10] , and is probably identical to the last. The human homologues of these loci are linked and lie on the long arm of chromosome 19, known as 19q [11] .
We have studied three large British families segregating for MH susceptibility to see if a mutated gene on chromosome 19q may underlie this condition.
METHODS

Families
Patients are referred to the Leeds MH Investigation Unit after a suspected MH anaesthetic reaction. If the proband has survived and is found to be susceptible to malignant hyperthermia, other close relatives are invited to have a diagnostic muscle biopsy. If the proband has died, family studies are initiated with the parents, if possible. Blood was collected from members of three, large triple-generation families (LMH3, LMH5 and LMH6) which had been studied in this way. The pedigrees of these families are shown in figure 1. These families were selected because at least one member of each had had an episode of fulminant MH, and because the in vitro contracture tests in the family members gave results which permit definite diagnosis. In two of these families, the proband had died from MH; in the other family, there were two probands, one of whom died and the other survived. DNA was extracted from peripheral blood samples using standard methods [12] . Typing of alleles at genetic marker loci was performed as described below, using Southern blotting and microsatellite amplification procedures. The results from these genetic typings were used for linkage analysis.
Southern blot analysis
Southern blots of genomic DNA digested with the appropriate restriction enzyme were hybridized with DNA probes to reveal the restriction fragment length polymorphisms (RFLP) [13] described in table I. The pattern observed on an autoradiograph showing an RFLP with the probe for D19S7 is shown in figure 2 .
Hypervariable microsatellites
The human genome contains large numbers of very simple repeat sequences, such as the bases (CA) n where n may vary from 5 to about 20. Although their function (if any) is uncertain, they are found through many of the non-coding regions of chromosomes. The length of the repeat unit at any one chromosomal position usually varies from person to person (or chromosome to chromosome), so that typically five or more different lengths of these repeat sequences are present in the population. The consequence of this is that the length of the repeat unit is highly informative as a marker which may be used in the same way as RFLP for following the inheritance of individual chromosomes in family studies. For this reason, hypervariable microsatellite marker loci are being used increasingly in gene mapping and genetic diagnosis [14] . A marker of this type is visualized by amplifying the region containing the simple repeat from unique genomic sequences which have been identified as flanking it on each side, using the polymerase chain reaction. The length of the two repeat units found on the two chromosomes in each individual may then be determined by high resolution gel electrophoresis. Polymerase chain reactions to amplify the hypervariable regions were carried out essentially as described previously [15] , except that radiolabelled phosphate (dCTP) was used to label the DNA product. The primer sequences used specifically amplified the hypervariable microsatellite regions of Mfd5 and Mfd9, corresponding to the loci APOC2 and D19S47, respectively. Both markers are known to be located on chromosome 19q [11] . The pattern of bands observed on an autoradiograph corresponding to alleles of the D19S47 locus is illustrated in figure 3 .
Linkage analysis
Linkage analysis was performed using the computer program LINKAGE v5.03 [16] . For the purpose of these linkage analyses, calculations have included the following assumptions in line with the recommendations of the genetics section of the European MH Group: a false negative rate on contracture testing of 2 %; a false positive rate on contracture testing of 2 %; frequency of the MH susceptibility allele 1 in 10000 in the population (corresponding to an incidence of 1 in 5000).
The LINKAGE program calculates the likelihood of obtaining the observed results with a specified degree of linkage, 0, between the susceptibility gene and the marker locus, compared with the likelihood of obtaining the same results in the absence of linkage. These likelihoods can be calculated for all degrees of recombination, 0, between 0.0 (complete linkage) and 0.5 (no linkage-that is, 50% recombination). By convention, relative likelihoods are expressed in the form of an odds ratio (for example, 10:1) against obtaining the observed linkage by chance. These likelihoods are then reported as logarithms (log 10 ) of the likelihood, and are known as the "lod" (log odds) score. In this form, the likelihoods from different families can be combined A lod score of + 3 is generally regarded as sufficient to establish a putative linkage in the absence of previous data; however, a lod score of +2 (corresponding to odds of 100:1) may be regarded as confirming the linkage for subsequent families. A lod score of -2 or less is taken as evidence excluding genetic linkage over the region where it applies around the marker locus because recombination has been found between the disease gene and the marker. Lod scores calculated by the LINKAGE program can be tabulated for each pedigree and each marker for several values of the recombination fraction, 0, from 0.001 (0.1 % recombination) up to 0.5. Close linkage is demonstrated between MH susceptibility and D19S47, the maximum lod score of + 2.11 being found at a recombination fraction of 0.075. Significant linkage has not, however, been demonstrated in any individual family, possibly because the marker was not fully informative. The MH gene is located more distantly from APOC2, with a maximum lod score from all three families of + 1.19 at a recombination fraction of 0.20. The region around APOC2 itself is excluded in family LMH3 (lod score less than -2). Linkage to the region of the marker Dl 9S7, which is located much nearer to the centromere of chromosome 19 and the other markers, is excluded for two of the families (LMH3 and LMH6). [7] and North American [17] families. The ryanodine receptor is a protein which contains a calcium release channel in the sarcoplasmic reticulum of skeletal muscle, so RYR1 is attractive as a candidate gene for MH susceptibility. There is physiological evidence implicating an abnormality of the ryanodine receptor in both porcine [18] and human [19] MH susceptibility.
RESULTS
Results of the in vitro
It is important to stress that the families in this present study were chosen because the typing of each individual as susceptible or non-susceptible was regarded as firm on the basis of the muscle contracture tests. The results presented here strongly suggest that the gene for MH susceptibility in one or more of these three British families is located in the same region of chromosome 19q. Whether or not RYR1, rather than another gene in the same region, is responsible for MH susceptibility in some or all of the families showing linkage to chromosome 19q is the subject of continuing work.
The question of genetic heterogeneity within MH susceptibility must also be examined. Families from North America and Central Europe have been reported which apparently exclude the relevant region of chromosome 19q from linkage with MH susceptibility [20, 21] . Indeed, it is possible that another region may be involved in one or two of the families reported here. Further studies on more families are needed to establish the proportions of families with MH susceptibility which map to chromosome 19 and to other regions of the genome. It also needs to be established if there is any correlation between the degree of sensitivity of the muscle of susceptible individuals to the in vitro contracture tests and linkage to chromosome 19. To facilitate progress in answering this question, we suggest that reports in this area include full contracture data, comprising the drug threshold for contracture, the strength of contracture at that threshold and the strength of contracture at 2% halothane (corresponding to 0.44 mmol litre" 1 ) and caffeine 2 mmol litre" 1 , respectively. In order to preserve international conformity, we have accepted the linkage analysis parameters for MH agreed by the genetics section of the European Malignant Hyperthermia Group. We think that these confidence limits are conservative when applied to our own data, and believe that this constitutes a suitable safeguard against drawing false conclusions.
Until the questions regarding the genetic heterogeneity of MH are resolved, it is clearly inappropriate to use the linkage of DNA marker loci as a diagnostic test for MH susceptibility in place of muscle contracture testing in a recognized centre.
